Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodriguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I.
Steeghs N, et al. Among authors: schmid d.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-3567. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38630781